Want to see GB:SUN full AI Analyst Report?
Surgical Innovations (SUN) AI Stock Analysis
Surgical Innovations
(LSE:SUN)
The score is held back primarily by weak financial performance (continued losses and soft revenue), partially offset by a low-debt balance sheet and a rebound to positive operating/free cash flow in 2025. Technically, the stock shows positive trend/momentum, but the extremely high RSI suggests the move may be overextended. Valuation is also a constraint because the negative P/E reflects lack of profitability.
Surgical Innovations (SUN) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 3.73M
- Dividend Yield
- ―
- Average Volume (3M)
- 704.36K
- Price to Earnings (P/E)
- -4.0
- Beta (1Y)
- 0.01
- Revenue Growth
- -3.68%
- EPS Growth
- 20.00%
- Country
- UK
- Employees
- 93
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Surgical Innovations Business Overview & Revenue Model
Company Description
Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and precisio...
How the Company Makes Money
Surgical Innovations makes money primarily by selling minimally invasive surgical instruments and related devices to healthcare providers. Revenue is generated from the commercialisation of its product portfolio, which includes both disposable (singl...
Surgical Innovations Financial Statement Overview
Summary
Mixed fundamentals: revenue has been flat-to-down and profitability remains negative (net loss in 2025 after a larger loss in 2024). Offsetting this, leverage is low (debt-to-equity ~0.09) and 2025 cash flow improved to positive operating and free cash flow, indicating better liquidity/cash conversion even while earnings are still weak.
Income Statement
34NegativeBalance Sheet
62PositiveCash Flow
56Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.48M | 11.60M | 11.95M | 12.01M | 11.34M | 9.13M |
| Gross Profit | 2.88M | 3.05M | 3.44M | 3.45M | 3.92M | 3.13M |
| EBITDA | -410.00K | -73.00K | -99.00K | 161.00K | 628.00K | 247.00K |
| Net Income | -1.16M | -895.00K | -1.94M | -509.00K | 264.00K | -456.00K |
Balance Sheet | ||||||
| Total Assets | 10.87M | 11.64M | 12.24M | 14.32M | 15.60M | 15.72M |
| Cash, Cash Equivalents and Short-Term Investments | 361.00K | 813.00K | 195.00K | 1.21M | 2.20M | 3.64M |
| Total Debt | 587.00K | 665.00K | 1.24M | 1.66M | 2.16M | 2.79M |
| Total Liabilities | 3.47M | 4.00M | 3.70M | 3.84M | 4.63M | 5.05M |
| Stockholders Equity | 7.40M | 7.65M | 8.54M | 10.48M | 10.96M | 10.66M |
Cash Flow | ||||||
| Free Cash Flow | 968.00K | 508.00K | -409.00K | -288.00K | -592.00K | -1.09M |
| Operating Cash Flow | 1.01M | 569.00K | -74.00K | 400.00K | 486.00K | -433.00K |
| Investing Cash Flow | -206.00K | -227.00K | -335.00K | -688.00K | -1.08M | -657.00K |
| Financing Cash Flow | 28.00K | 271.00K | -626.00K | -672.00K | -935.00K | -532.00K |
Surgical Innovations Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SUN, the sentiment is Negative. The current price of 0.40 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.41, and below the 200-day MA of 0.45, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 0.92 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SUN.
Surgical Innovations Peers Comparison
Overall Rating
GB:SN72Outperform
GB:AMS67Neutral- GB:SUN55Neutral
GB:CREO38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:SN | 72Outperform | GBP 9.27B | 19.52 | 12.25% | 2.66% | 2.17% | 27.33% |
| GB:AMS | 67Neutral | GBP 611.34M | 166.18 | 1.44% | 1.66% | 6.05% | -60.00% |
| GB:SUN | 55Neutral | GBP 3.73M | -4.00 | -15.47% | ― | -3.68% | 20.00% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:CREO | 38Underperform | GBP 51.09M | -2.51 | -38.29% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:SUN | Surgical Innovations Group Plc | 0.40 | -0.18 | -31.03% | |
| GB:AMS | Advanced Medical Solutions | 282.50 | 67.49 | 31.39% | |
| GB:CREO | Creo Medical | 11.38 | 0.13 | 1.11% | |
| GB:SN | Smith & Nephew (UK) | 1107.50 | -251.88 | -18.53% |
Surgical Innovations Corporate Events
Surgical Innovations Holds Revenue Steady, Completes MDR Transition and Brings in New CEO
PositiveSurgical Innovations reported broadly flat first-half 2026 revenue of £6.02 million, with margins modestly improved but profitability down as adjusted EBITDA slipped to £0.03 million. Net debt remained stable at £0.3 million and the co...
Surgical Innovations Names MedTech Veteran Alex Warnock as New CEO
PositiveSurgical Innovations Group plc has announced a leadership transition in which long-serving chief executive David Marsh will step down as CEO on 1 October 2026 to become a non-executive director, continuing to support the company through key relations...
Surgical Innovations Sets Date for Interim Results and Investor Briefing
NeutralSurgical Innovations Group plc, an AIM-quoted designer and manufacturer of minimally invasive surgical technologies, markets resposable port access systems, instruments and retraction devices via its Elemental Healthcare subsidiary in the U.K. and th...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026